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assessed and assigned to an ordinal scale representing
ascending severity of disease. Rating scale was trans-
formed by the Torrance transformation. Multivariate
stepwise regression with a log-transformed outcome was
used to calculate utilities for the health states adjusted for
age, gender, viral status, co-morbidity, and short-term
effect of current antiviral medication. RESULTS: Quality-
of-life values based on RS (r = 0.24; p < 0.001) and EQ-
5D (r = 0.13; p < 0.019) showed signiﬁcant correlation
with the severity of disease scale. Overall, RS resulted in
higher utilities than EQ-5D. Depending on health state
and instrument, utilities ranged from 0.92 (mild hepati-
tis, RS) to 0.72 (hepatocellular carcinoma, EQ-5D).
Short-term relative utility reduction during the time of
treatment with combination therapy was 15% for RS (p
< 0.001) and 14% for EQ-5D (p < 0.001). RS and EQ-
5D were highly and signiﬁcantly correlated (r = 0.64, p <
0.001) suggesting that the results are robust. CONCLU-
SION: Patients with CHC appear to experience a lower
quality of life compared to the general population. This
study suggests that the Torrance transformation of the
rating scale or EuroQoL from patient reports are feasible
and robust instruments for assessing patient preferences
regarding quality of life. These results can be used in cost-
effectiveness analyses in studies of patients with chronic
hepatitis C.
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OBJECTIVES: Recently, a new index score to measure
health status has been developed based on items from the
SF36, the so-called SF6D. To assess its merits and valid-
ity we compared baseline and change statistics of the
SF6D and the EQ5D in a group of patients undergoing
coronary revascularisation. METHODS: A consecutive
cohort of 535 patients enrolled in a randomised con-
trolled trial comparing off-pump coronary artery bypass
surgery (CABG) with on-pump CABG and percutaneous
transluminalcoronary angioplasty (PTCA) was adminis-
tered the SF-36 and the EQ5D questionnaires pre- and
post-intervention. The SF6D “utility” was computed
according to the scoring system that recently became
available. RESULTS: We observed no differences in
change score across the arms of trials. Therefore, data on
all patients were analysed together. There were more
missing in the SF6D than in the EQ5D: 12.7% versus
4.7%. All baseline and change variables had non-normal
distributions. Although baseline mean values were com-
parable (SF6D 0.625; EQ5D 0.645, t-test: p = 0.09)
median values differed signiﬁcantly (SF6D 0.603; EQ5D
0.691, Wilcoxon matched pairs test: p = 0.0009). Median
change from baseline as measured with the SF6D was sig-
niﬁcantly lower than change as measured with the EQ5D
(0.024 versus 0.052, p = 0.00002). CONCLUSIONS: The
SF6D and the EQ5D appear to result in similar baseline
scores using the recommended mean values. However,
both the median baseline values and change scores dif-
fered signiﬁcantly. This indicates that the SF6D and the
EQ5D measure different concepts of health status and
cannot be used as equivalents.
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OBJECTIVES: To establish whether treatment with 
adalimumab (D2E7, Abbott) improves health utility in
patients with moderate/severe RA. METHODS: A total
of 544 active RA patients from 10 European countries,
Canada and Australia were randomized to receive 
adalimumab or placebo (other disease modifying anti-
rheumatic drugs were discontinued). For 474 patients, the
Health Utilities Index-Mark 3 (HUI3) measured health
utility at baseline, month 3 and 6. An HUI3 score of 1
represents perfect health and 0 represents death. HUI3
change from baseline was estimated for each treatment
group in a linear regression controlling for age, sex,
country, and baseline disease severity (measured by the
Disease Activity Score-28). This analysis includes the 430
patients with non-missing values for these variables.
RESULTS: At baseline, HUI3 scores were comparable
across treatment groups, but mean HUI3 (0.266) was far
below population norms (patients with mild RA typically
score above 0.70). Older patients and patients with more
severe arthritis had lower HUI3 (p = 0.034 and p < 0.001,
respectively). U.K. patients had lower HUI3 than patients
from Australia (p = 0.002), Canada (p = 0.011) or
Germany (p = 0.016). Sex was not a signiﬁcant predictor
of baseline HUI3 scores. At month 3, least squares mean
HUI3 scores (controlling for age, sex, country and base-
line disease severity) improved by 0.160 for the 40mg
every other week adalimumab group, a statistically sig-
niﬁcant and clinically meaningful change compared to 
the placebo group’s 0.064 improvement (p = 0.011). At
month 6, the improvement was 0.166 for the 40mg every
other week adalimumab group compared to 0.078 for the
placebo group (p = 0.029). Patients with more severe RA
improved more than others (p < 0.001). Age, sex, and
country were not predictors of improvement. CONCLU-
SIONS: Adalimumab monotherapy improves patients’
health utility by statistically and clinically meaningful
amounts within three months of treatment initiation and
sustains health utility at month 6.
